Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule
Tae-Wook Kang1, Soon Won Choi1, Se-Ran Yang2
11] Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea [2] BK21 PLUS Program for Creative Veterinary Science Research, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul National University [3].
Abstract:
Glioblastoma multiforme is the most common malignant brain tumor in adults, with an average survival of less than one year due to its resistance to therapy. Recent studies reported that GBM initiates from CD133-expressing cancer stem cells (CSC). However, the efficacy of CSC targeting is limited. A newly developed approach in cancer treatment is the forced differentiation of cancer cells. Here, we show that the treatment of the novel small molecule, CG500354, into CD133-expressing human primary GBM cells induces growth arrest by cell cycle regulators, p53, p21, p27 and phase-specific cyclins, and neural differentiation, as confirmed by neural progenitor/precursor markers, nestin, GFAP and Tuj1. When GBM-derived cells caused the tumors in NOD/SCID mice, CG500354 induced GBM-derived cells differentiation into Tuj1 and GFAP expressing cells. We next demonstrated that CG500354 plays a tumor-suppressive role via cAMP/CREB signaling pathway. CG500354 increases not only the extracellular cAMP level but also the protein level of PKA and CREB. Additionally, both mimetic substances, Forskolin and Rolipram, revealed comparable results with CG500354. Our findings indicate that induction of growth arrest and neural differentiation via cAMP/CREB signaling pathway by CG500354 treatment suggests the novel targeting of PDE4D in the development of new drugs for brain tumor therapy.
Insights
A novel small molecule, CG500354, effectively halts glioblastoma multiforme growth and promotes neural differentiation by targeting the cAMP/CREB pathway. This approach offers a promising new avenue for brain tumor therapy.
Area of Science:
- Oncology
- Neuroscience
- Molecular Biology
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis due to therapeutic resistance.
- Cancer stem cells (CSCs), identified by CD133 expression, are implicated in GBM initiation, but CSC-targeting therapies show limited efficacy.
- Forced differentiation of cancer cells is an emerging therapeutic strategy.
Purpose of the Study:
- To investigate the therapeutic potential of the novel small molecule CG500354 in treating glioblastoma multiforme.
- To elucidate the mechanism of action of CG500354, focusing on its effects on cancer cell growth, differentiation, and signaling pathways.
Main Methods:
- Treatment of CD133-expressing human primary GBM cells and GBM-derived tumors in NOD/SCID mice with CG500354.
- Analysis of cell cycle regulators (p53, p21, p27, cyclins) and neural progenitor/precursor markers (nestin, GFAP, Tuj1).
- Investigation of the cAMP/CREB signaling pathway, including measurement of cAMP levels and protein expression of PKA and CREB. Use of Forskolin and Rolipram as mimetic substances.
Main Results:
- CG500354 induced growth arrest in GBM cells via cell cycle regulators and promoted neural differentiation, confirmed by marker expression.
- In vivo studies showed CG500354 induced differentiation of GBM-derived cells into Tuj1 and GFAP expressing cells.
- CG500354 demonstrated a tumor-suppressive role by increasing extracellular cAMP and PKA/CREB protein levels, mimicking effects of Forskolin and Rolipram.
Conclusions:
- CG500354 promotes glioblastoma growth arrest and neural differentiation through the cAMP/CREB signaling pathway.
- Targeting phosphodiesterase 4D (PDE4D) via CG500354 represents a novel therapeutic strategy for brain tumors.
- This study highlights the potential of CG500354 as a new drug candidate for glioblastoma therapy.
More Related Videos
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014